[go: up one dir, main page]

AR063362A1 - Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada - Google Patents

Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada

Info

Publication number
AR063362A1
AR063362A1 ARP070104694A ARP070104694A AR063362A1 AR 063362 A1 AR063362 A1 AR 063362A1 AR P070104694 A ARP070104694 A AR P070104694A AR P070104694 A ARP070104694 A AR P070104694A AR 063362 A1 AR063362 A1 AR 063362A1
Authority
AR
Argentina
Prior art keywords
palonosetron
dosage forms
lipophilic
water
weight
Prior art date
Application number
ARP070104694A
Other languages
English (en)
Inventor
Enrico Braglia
Riccardo Braglia
Daniele Bonadeo
Giorgio Calderari
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063362(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of AR063362A1 publication Critical patent/AR063362A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • A61K9/5057Gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formas de dosificacion orales solidas, del clorhidrato de palonosetron, métodos para usar las formas de dosificacion para tratar el vomito, y métodos para hacer las formas de dosificacion. Las formas de dosificacion han mejorado la estabilidad y biodisponibilidad, y están preferiblemente bajo la forma de cápsulas rellenas de líquido. Reivindicacion 1: Una cápsula de gel blanda para administracion oral que comprende: a) un recubrimiento externo de gel blando que tiene una permeabilidad del oxígeno de menos de alrededor de 1.0 x 10-3 ml.cm (cm2.24 atmosferas -hora); y b) una composicion interna líquida lipofílica del relleno comprende: i) mayor que alrededor de 50% de peso de uno o más componentes lipofílicos; ii) de cerca de 1 a cerca de 20% de peso de agua homogeneizada en dicho uno o más componentes lipofílicos; iii) de cerca de 0.05 mg. a cerca de 2.0 del palonosetron como clorhidrato de palonosetron solubilizado o disperso en dicha agua; y iv) de cerca de 0.5 a cerca de 8% de peso de un tensioactivador. Reivindicacion 19: Un método de optimizar la biodisponibilidad y la estabilidad del palonosetron en una cápsula de gelatina de palonosetron comprende: a) proporcionar un recubrimiento externo de la gelatina blanda que tiene una permeabilidad de oxígeno de menos de cerca de 1.0 x 10-3 ml.cm (cm2.24 hora atmosferas); y b) preparacion de una composicion de relleno por pasos que comprenden: i) proporcionar de cerca de 0.05 mg. a cerca de 2.0 de palonosetron como clorhidrato de palonosetron en donde dicho palonosetron comprende Cpd1 en una cantidad de menos de 3.0% de peso; ii) disolucion o dispersion de dicho palonosetron en agua para formar una mezcla acuosa preparada de antemano; iii) mezclar dicha mezcla acuosa preparada de antemano con uno o más excipientes lipofílicos, en un cociente de peso de la mezcla acuosa preparada de antemano a los excipientes lipofílicos menos de 30:70, para formar una composicion lipofílica miscible u homogénea del relleno; iv) mezcla de un tensioactivador con dicha agua, dicha mezcla acuosa preparada de antemano, o dicha composicion del relleno; y v) equilibrio de las cantidades de tensioactivador y de agua en dicha composicion del relleno para facilitar la biodisponibilidad de dicha cápsula de gelatina del palonosetron cuando es injerida oralmente, y para disminuir el grado de degradacion del palonosetron; y c) llenar dicho recubrimiento externo con dicha composicion del relleno.
ARP070104694A 2006-10-24 2007-10-24 Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada AR063362A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85434206P 2006-10-24 2006-10-24

Publications (1)

Publication Number Publication Date
AR063362A1 true AR063362A1 (es) 2009-01-21

Family

ID=38921772

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104694A AR063362A1 (es) 2006-10-24 2007-10-24 Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada

Country Status (35)

Country Link
US (2) US20080152704A1 (es)
EP (1) EP1940366B9 (es)
JP (1) JP5144527B2 (es)
KR (1) KR101441459B1 (es)
CN (1) CN101573106B (es)
AR (1) AR063362A1 (es)
AT (1) ATE427742T1 (es)
AU (1) AU2007308378B2 (es)
BR (1) BRPI0718497B1 (es)
CA (1) CA2666512C (es)
CL (1) CL2007003055A1 (es)
CO (1) CO6160289A2 (es)
CR (1) CR10728A (es)
CY (1) CY1109914T1 (es)
DE (1) DE602007000856D1 (es)
DK (1) DK1940366T3 (es)
EA (1) EA016455B1 (es)
ES (1) ES2325339T3 (es)
GT (1) GT200900096A (es)
HN (1) HN2009000785A (es)
HR (1) HRP20090341T1 (es)
IL (1) IL198225A (es)
ME (1) ME01949B (es)
MX (1) MX2009004461A (es)
NO (1) NO342353B1 (es)
NZ (1) NZ576237A (es)
PL (1) PL1940366T3 (es)
PT (1) PT1940366E (es)
RS (1) RS50842B (es)
SI (1) SI1940366T1 (es)
SV (1) SV2009003238A (es)
TW (1) TWI367212B (es)
UA (1) UA97653C2 (es)
WO (1) WO2008049552A1 (es)
ZA (1) ZA200902773B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ569984A (en) * 2006-01-27 2011-06-30 Eurand Inc Drug delivery systems comprising weakly basic drugs and organic acids
US20070190145A1 (en) * 2006-01-27 2007-08-16 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
WO2010077669A2 (en) 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102048705B (zh) * 2009-11-10 2012-07-18 齐鲁制药有限公司 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法
JP2013510843A (ja) * 2009-11-13 2013-03-28 ヘルシン ヘルスケア ソシエテ アノニム パロノセトロン代謝産物先行出願との関連本出願は2009年11月13日に出願された米国仮出願第61/260,916号の優先権を主張する。
LT2722045T (lt) * 2009-11-18 2016-09-26 Helsinn Healthcare Sa Kompozicija skirta gydyti centralizuotai kontroliuojamą pykinimą ir vėmimą
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
JP2014530249A (ja) 2011-10-18 2014-11-17 ヘルシン ヘルスケア ソシエテ アノニム ネツピタントおよびパロノセトロンの治療学的組合せ
CN107137374B (zh) * 2012-06-02 2020-04-07 正大天晴药业集团股份有限公司 帕洛诺司琼的固体药物组合物
RU2015144543A (ru) * 2013-03-19 2017-04-27 Галеникум Хелс С.Л. Фармацевтические композиции, содержащие активное вещество
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
KR20150073866A (ko) 2013-12-23 2015-07-01 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
JP2019019067A (ja) * 2017-07-13 2019-02-07 ニプロ株式会社 液体製剤
CN111205283A (zh) * 2020-01-20 2020-05-29 广州九植医药科技有限公司 一种盐酸帕洛诺司琼有关物质b的合成方法
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
EP4633608A1 (en) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
IL321446A (en) 2022-12-12 2025-08-01 Tiefenbacher Alfred E Gmbh & Co Kg Fixed-dose combination including netopitant and flunosterone

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
US4182914A (en) * 1974-01-22 1980-01-08 Nippon Oil Company Limited Process for continuously producing diisopropyl ether
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
EP0498466B1 (en) * 1985-04-27 2002-07-24 F. Hoffmann-La Roche Ag Indazole-3-carboxamide and -3-carboxylic acid derivatives
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
FI98367C (fi) * 1989-11-28 1997-06-10 Syntex Inc Menetelmä uusien terapeuttisesti käyttökelpoisten trisyklisten, typpipitoisten yhdisteiden valmistamiseksi
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2823118B1 (fr) * 2001-04-04 2004-03-19 Lavipharm Lab Inc Nouvelle composition filmogene a usage topique et son utilisation pour la delivrance d'agents actifs
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents

Also Published As

Publication number Publication date
CO6160289A2 (es) 2010-05-20
PT1940366E (pt) 2009-06-17
NZ576237A (en) 2011-12-22
SV2009003238A (es) 2009-11-09
TWI367212B (en) 2012-07-01
HN2009000785A (es) 2011-10-14
CA2666512C (en) 2014-05-27
NO342353B1 (no) 2018-05-07
IL198225A (en) 2013-03-24
AU2007308378A1 (en) 2008-05-02
DK1940366T3 (da) 2009-06-29
MX2009004461A (es) 2009-09-16
WO2008049552A1 (en) 2008-05-02
JP2009507933A (ja) 2009-02-26
CN101573106B (zh) 2013-07-24
CA2666512A1 (en) 2008-05-02
BRPI0718497A2 (pt) 2014-07-08
US20170035748A1 (en) 2017-02-09
JP5144527B2 (ja) 2013-02-13
HRP20090341T1 (hr) 2009-07-31
KR20090073234A (ko) 2009-07-02
ATE427742T1 (de) 2009-04-15
EP1940366B1 (en) 2009-04-08
CY1109914T1 (el) 2014-09-10
PL1940366T3 (pl) 2009-09-30
CR10728A (es) 2009-07-23
ME01949B (me) 2010-08-31
CN101573106A (zh) 2009-11-04
US20080152704A1 (en) 2008-06-26
CL2007003055A1 (es) 2008-03-24
KR101441459B1 (ko) 2014-09-18
SI1940366T1 (sl) 2009-08-31
ZA200902773B (en) 2010-03-31
EA016455B1 (ru) 2012-05-30
EP1940366B9 (en) 2009-12-02
UA97653C2 (ru) 2012-03-12
GT200900096A (es) 2011-08-29
EA200970396A1 (ru) 2009-10-30
RS50842B (sr) 2010-08-31
TW200827355A (en) 2008-07-01
HK1117769A1 (en) 2009-01-23
BRPI0718497B1 (pt) 2024-02-06
ES2325339T3 (es) 2009-09-01
NO20091945L (no) 2009-05-25
AU2007308378B2 (en) 2013-02-21
EP1940366A1 (en) 2008-07-09
IL198225A0 (en) 2009-12-24
DE602007000856D1 (de) 2009-05-20

Similar Documents

Publication Publication Date Title
AR063362A1 (es) Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada
ECSP10010395A (es) Formulacion de capsula
ES2665464T3 (es) Forma de dosificación oral sólida que contiene microcápsulas sin costuras
PH12015502134B1 (en) Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
BRPI0514180A (pt) composto, composição farmacêutica, uso de um composto, kit farmaceuticamente útil adaptado para administração oral diária, e, métodos de preparação de um composto, e de contracepção em um mamìfero
RU2013112353A (ru) Фосфолипидный депо-препарат
WO2007075475A3 (en) Gastric reflux resistant dosage forms
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
RS54588B1 (sr) Tečni nazalni sprej koji sadrži nisku dozu naltreksona
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
AR081187A1 (es) Formulaciones inyectables parasiticidas de levamisol y lactonas macrociclicas. metodo de preparacion. metodo de tratamiento.
RU2015134148A (ru) Галеновая форма для введения активного действующего вещества
ES2197781A1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
AR042598A1 (es) Composiciones de acetaminofeno
PE20050414A1 (es) Formulacion farmaceutica oral que comprende un antagonista de la bomba de protones y un excipiente basico
ATE462419T1 (de) Orale pharmazeutische zusammensetzung für weichkapseln mit vinorelbin und behandlungsverfahren
ATE410150T1 (de) Neue weichgelatinekapseln
MX2008001532A (es) Composicion farmaceutica que contiene indometacina y/o acemetacina.
WO2005107709A3 (en) Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
HRP20240525T1 (hr) Pripravak na bazi lipida za oralnu primjenu antagonista bradikininskog b2-receptora
AR049846A1 (es) Preparaciones farmaceuticas de derivados de la piperazina
KR102684071B1 (ko) 액체 의약 조성물 및 의약품
EA200700524A1 (ru) Препараты для перорального применения с эффектом замедленного действия при приеме api вместе с пищей
WO2007062262A3 (en) Gelatinous medicament formulation and method of administration

Legal Events

Date Code Title Description
FB Suspension of granting procedure